From AI Euphoria to Energy Fear: The Market‘s Pivot as Middle East Conflict Reshapes Portfolios
From AI Adoption Surge to Capex Scrutiny: Volatility Risks Loom for U.S. Financial Markets
Airlines and Tourism Stocks Face Pressure as Global Risks Escalate
Fundamentals for Revvity, Inc.
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revenue projections:
Revvity, Inc.'s revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.
Financial Ratios:
| currentRatio | 1.682000 |
|---|---|
| forwardPE | 16.091888 |
| debtToEquity | 46.869000 |
| earningsGrowth | 0.125000 |
| revenueGrowth | 0.059000 |
| grossMargins | 0.547740 |
| operatingMargins | 0.200670 |
| trailingEps | 2.060000 |
| forwardEps | 6.001160 |
RVTY's current ratio of 1.682 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, RVTY can comfortably cover its liabilities, reflecting a strong financial outlook.
RVTY's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
RVTY's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
RVTY's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.
Price projections:
Revvity, Inc.'s price projections have been steadily revised down, pointing to declining confidence in the company's outlook. This suggests that analysts are becoming more conservative in their expectations for Revvity, Inc.'s future performance.
Insider Transactions:
RVTY experienced 9 selling transactions, with market price of 104.93888854980469.There were no sell transactions recorded during the period under consideration.The higher volume of buys compared to sells near current RVTY price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.
Recommendation changes over time:
RVTY has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view RVTY as a reliable choice for their money, offering a promising avenue for future growth and financial gains.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
Retailers at a Crossroads: Analyzing the Shift to Value in January Sales
Corporate Governance in the Crosshairs: SEC Policy Shifts and the Litigation Wave